AbbVie (ABBV)

AI-powered earnings call analysis for AbbVie. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

15 episodes 5 languages

Next Episode

AbbVie earnings call scheduled for Oct 29, 2026 (before market open)

New episode expected Oct 30, 2026

Latest Episode

Q2 2026 Earnings

6:08 • 7/31/2026

AbbVie (ABBV) - Q2 2026

0:00

6:08

Speed:

Q2 2026 Earnings

8:36 • 2026/7/31

AbbVie (ABBV) - Q2 2026

0:00

8:36

Speed:

Q2 2026 Earnings

9:10 • 31/07/2026

AbbVie (ABBV) - Q2 2026

0:00

9:10

Speed:

Q2 2026 Earnings

9:09 • 31/7/2026

AbbVie (ABBV) - Q2 2026

0:00

9:09

Speed:

Q2 2026 Earnings

7:24 • 31.7.2026

AbbVie (ABBV) - Q2 2026

0:00

7:24

Speed:

All Episodes

EN - English (3) CN - 中文 (3) FR - Français (3) ES - Español (3) DE - Deutsch (3)

Q2 2026 Earnings

6:08

AbbVie delivered strong Q2 with $17.0B revenue (+10.2%), adjusted EPS of $3.65, raising full-year guidance to $67.6B amid robust growth in immunology and neuroscience.

Q1 2026 Earnings

6:41

AbbVie delivered strong Q1 2026 results with $15.0B revenue (+12.4%) and $2.65 adjusted EPS, raising full-year guidance to $14.08-$14.28 on robust immunology and neuroscience momentum, while advancing transformational pipeline programs including Skyrizi combinations and obesity therapeutics.